GloStrips, Fluorescein Sodium Ophthalmic Strips USP (0.6 mg Fluorescein), Rx Only, a) 100 strips ...
FDA Drug Recall #D-0462-2024 — Class II — April 19, 2024
Recall Summary
| Recall Number | D-0462-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 19, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Nomax Inc |
| Location | Saint Louis, MO |
| Product Type | Drugs |
| Quantity | 15,056 cartons |
Product Description
GloStrips, Fluorescein Sodium Ophthalmic Strips USP (0.6 mg Fluorescein), Rx Only, a) 100 strips per carton, NDC 51801-003-40; b) 300 strips per carton, NDC 51801-003-50, Nomax, Inc., St. Louis, MO 63123.
Reason for Recall
Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot #s: a) 14904, Exp. 06/30/2024; Lot 14938, Exp. 07/31/2024; b) Lot 14931, Exp. 06/30/2024
Other Recalls from Nomax Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0465-2024 | Class II | FUL-GLO, Fluorescein Sodium Ophthalmic Strips U... | Apr 19, 2024 |
| D-0463-2024 | Class II | GloStrips, Fluorescein Sodium Ophthalmic Strips... | Apr 19, 2024 |
| D-0464-2024 | Class II | FUL-GLO, Fluorescein Sodium Sterile Ophthalmic ... | Apr 19, 2024 |
| D-0387-2021 | Class III | Dry Eye Test, Fluorescein Sodium, Ophthalmic St... | Apr 13, 2021 |
| D-0962-2015 | Class III | Rose Bengal GloStrips (rose bengal) Ophthalmic ... | Mar 24, 2015 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.